Therefore, to further refine the molecular classification of astrocytic tumors, we incorporated the other two prognostic markers into the model, IDH1/2 mutational status and Ki-67 protein expression, which were also associated with the clinical outcome of patients with astrocytic tumors.(Fig.3c, Fig.3d, Table 2). This evidence concerns the gene MKI67 and astrocytic tumor.